A Systematic Literature Review of the Effectiveness of CDK 4/6 Inhibitors for First-Line Treatment of HR+/HER2- Advanced/Metastatic Breast Cancer: A Comparison of Real-World Evidence.

Pluard T, Grinda T, Dienstmann R, Thill M, Korytowsky B, Chen C, Portuhay S, Salvo-Halloran EM, Samjoo IA, Harbeck N

Open source

DOI
10.3390/cancers18142362
Published
2026 Jul 22
Container
Cancers
Publisher
Not recorded
Open access
yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.3390/cancers18142362,
  title = {A Systematic Literature Review of the Effectiveness of CDK 4/6 Inhibitors for First-Line Treatment of HR+/HER2- Advanced/Metastatic Breast Cancer: A Comparison of Real-World Evidence.},
  author = {Pluard T and Grinda T and Dienstmann R and Thill M and Korytowsky B and Chen C and Portuhay S and Salvo-Halloran EM and Samjoo IA and Harbeck N},
  year = {2026},
  journal = {Cancers},
  doi = {10.3390/cancers18142362},
  url = {https://doi.org/10.3390/cancers18142362}
}

RIS

TY  - JOUR
TI  - A Systematic Literature Review of the Effectiveness of CDK 4/6 Inhibitors for First-Line Treatment of HR+/HER2- Advanced/Metastatic Breast Cancer: A Comparison of Real-World Evidence.
AU  - Pluard T
AU  - Grinda T
AU  - Dienstmann R
AU  - Thill M
AU  - Korytowsky B
AU  - Chen C
AU  - Portuhay S
AU  - Salvo-Halloran EM
AU  - Samjoo IA
AU  - Harbeck N
PY  - 2026
JO  - Cancers
DO  - 10.3390/cancers18142362
UR  - https://doi.org/10.3390/cancers18142362
ER  - 

APA

T, P., T, G., R, D., M, T., B, K., C, C., S, P., EM, S., IA, S., & N, H. (2026). A Systematic Literature Review of the Effectiveness of CDK 4/6 Inhibitors for First-Line Treatment of HR+/HER2- Advanced/Metastatic Breast Cancer: A Comparison of Real-World Evidence.. Cancers. https://doi.org/10.3390/cancers18142362

Source records